Drotrecogin alfa (aktiveret), som forefindes i en blod - eller plasmaprøve udtaget fra en patient, som får lægemidlet, vil gradvist blive neutraliseret af endogene plasmaprotease - inhibitorer, som findes i prøven.
Drotrecogin alfa (activated) that is present in a blood or plasma sample drawn from a patient who is being infused with the drug will be gradually neutralized by endogenous plasma protease inhibitors present in the sample.